IPP Bureau
Cupid receives Rs. 42 crore order from Tanzania
By IPP Bureau - February 28, 2025
We have big plans across our B2C and B2B businesses in India and abroad
Sanofi India declares 8% growth in net sales for Q4-2024
By IPP Bureau - February 28, 2025
Standalone profit from operations for Q4-2024 were Rs. 108 crore
Biocon Foundation marks 20 years of transforming lives
By IPP Bureau - February 28, 2025
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
Zydus Lifesciences to launch protection against new strain of influenza virus
By IPP Bureau - February 27, 2025
VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives
Borosil Scientific to shift unit at Ambad to Bharuch
By IPP Bureau - February 27, 2025
This will lead to the consolidation and optimization of the company's operations related to the manufacturing of ampoules and vials
USFDA issues Form 483 with 3 observations to Gland Pharma's Sterile APIs unit
By IPP Bureau - February 27, 2025
The observations issued are neither repeated observations nor related to data integrity
Briefs: Emcure and Relonchem
By IPP Bureau - February 27, 2025
USFDA inspection at Emcure Pharmaceuticals API facility
Caplin Steriles receives USFDA final approval for ANDA Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
By IPP Bureau - February 27, 2025
Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution is indicated for the reduction of elevated intraocular pressure
Senores Pharmaceuticals begins operations at greenfield API facility
By IPP Bureau - February 27, 2025
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
Venus Remedies secures in-licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
By IPP Bureau - February 27, 2025
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Glenmark Pharmaceuticals USA launches Epinephrine Injection USP
By IPP Bureau - February 27, 2025
This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
India’s CRDMO sector growth potential at $22 - $25 Billion by 2035: BCG-IPSO Report
By IPP Bureau - February 26, 2025
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
Merck unveils formulation and technology center in Navi Mumbai
By IPP Bureau - February 26, 2025
The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations
Cadila Pharmaceuticals opens advanced pharmaceutical warehouse
By IPP Bureau - February 26, 2025
FDA grants EUA to Aptitude’s Covid/flu multiplex test for OTC use
By IPP Bureau - February 26, 2025
